Digital health funding just rebounded – it doesn’t look like 2021

US digital health startups raised $7.4bn across 244 deals in the first half of 2026, up from $6.4bn over the same period last year (Rock Health). At first glance that might seem like HealthTech is on the up again, a return to form. But look a bit deeper and it’s a different story than the one we saw last time this much capital moved through the sector.

The last real peak was 2021, when global digital health funding hit over $50bn in a single year. The UK had its own moment inside that wave too: Oxford Nanopore’s London listing that autumn was one of the biggest biotech IPOs the market had seen, and we spent some of that year in the room ourselves, filming with their team on a project for the UK Government promoting British Life Sciences innovation to the world. It was a good year to be optimistic about HealthTech.

This isn’t that. Deal count across the sector has fallen by around 63% since 2022, even as total capital has recovered (Galen Growth). The money isn’t spreading wider, it’s concentrating into fewer, larger rounds, backing companies that have already proven they work rather than funding a broad wave of new ideas the way 2021 did.

It’s also worth being specific about where that investment is actually going, because it isn’t simply ‘AI’. Alongside AI-enabled clinical tools, one of the clearest beneficiaries this year has been revenue cycle management: the slightly unglamorous administrative and billing infrastructure that sits behind every health system. It’s not a flashy category, but it is one with obvious, provable return on investment – which is exactly what today’s more selective investors are looking for.

That’s also the real answer to why this is happening now, in a US economy that isn’t exactly booming. Healthcare has always been a hard sector for venture capital to make work: long sales cycles, fragmented buyers, and returns that don’t behave like consumer software. What’s changed isn’t that healthcare got easier. It’s that investors have adjusted their expectations to match it, backing real, demonstrable traction over speculative growth.

For companies in this position, that changes what actually needs to be built and shown – not a bigger vision. Evidence that the product works, at the scale and with the rigour a more sceptical investor, and a more sceptical regulator, will actually test.

And that’s a harder thing to design than it sounds. Proving a product works – clearly, credibly, and to someone whose job it is to doubt you is a design and communication challenge as much as a technical one: how the evidence is presented, how the product explains itself, how it holds up the moment someone starts pressing. It’s the work we do at Studiomade. If you’re raising, or preparing to, and want your product to withstand that kind of scrutiny, let’s talk.